NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The 'case for adoption' is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
1.1 The case for adopting the MAGEC system for spinal lengthening in children with scoliosis is supported by the evidence. Using the MAGEC system would avoid repeated surgical procedures for growth rod lengthening. This could reduce complications and have other physical and psychological benefits for affected children and their families.
1.2 The MAGEC system should be considered for use in children with scoliosis aged 2 years and over who need surgery to correct their spinal curvature, for example when conservative methods such as bracing or casting have failed.
1.3 Findings from cost modelling estimate that using the MAGEC system is cost saving compared with conventional growth rods from about 3 years after first insertion. The estimated cost saving per child after 6 years is around £12,077. The cost savings remained robust in sensitivity analyses. Further savings could be made by avoiding the need for spinal cord monitoring, which is sometimes used during conventional growth rod lengthening but is not needed when lengthening the MAGEC growth rods.